Form D · Biotechnology
Magenta Therapeutics, Inc.
Cambridge, MA · CIK 0001690585
Offering snapshot reported Apr 9, 2018 · SEC filing
- Reported sold
- $52.3M Offering amount: $52.3M
- Investors reported
- 23 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Apr 2, 2018 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Apr 9, 2018 | Initial | $52,299,655 | No comparison | 23 | SEC filing |
| May 5, 2017 | Initial | $46,000,000 | No comparison | 13 | SEC filing |
| Nov 23, 2016 | Initial | $17,718,974 | No comparison | 13 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-309660
Source: Form D, filed Apr 9, 2018. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Jeffrey Albers | Director |
| Michael Bonney | Director |
| Bruce Booth | Director |
| Alexis Borisy | Director |
| Blake Byers | Director |
| Thomas Daniel | Director |
| John Davis | Executive |
| Jason Gardner | Director, Executive |
| Amy Ronneberg | Director |
| Bastiano Sanna | Executive |
| David Scadden | Director |
| Zoran Zdraveski | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
50 Hampshire Street 8th Floor
Cambridge, MA, 02139
Cambridge, MA, 02139